Second, the follow-up was short, and a longer follow-up period is needed to examine whether 18F-FDG PET metabolic parameters on primary tumors can predict survival outcomes of HCC patients after treated with Lenvatinib in combination with PD-1 inhibitors as conversion therapy, followed by surgery. This evidence concerns the gene PDCD1 and hepatocellular carcinoma.